Cargando…

Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas

PURPOSE: The overall survival of clear cell renal cell carcinoma (ccRCC) is poor. Markers for early detection and progression could improve disease outcomes. This study aims to reveal the potential pathogenesis of ccRCC by integrative bioinformatics analysis and to further develop new therapeutic st...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Sheng, Shi, Guanyun, Pan, Zhengbo, Cheng, Weisong, Xu, Linfei, Lin, Xingzhang, Lin, Yongfeng, Zhang, Liming, Ji, Guanghua, Lv, Xin, Wang, Dongguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238222/
https://www.ncbi.nlm.nih.gov/pubmed/37275334
http://dx.doi.org/10.2147/IJGM.S409711
_version_ 1785053245481156608
author Liu, Sheng
Shi, Guanyun
Pan, Zhengbo
Cheng, Weisong
Xu, Linfei
Lin, Xingzhang
Lin, Yongfeng
Zhang, Liming
Ji, Guanghua
Lv, Xin
Wang, Dongguo
author_facet Liu, Sheng
Shi, Guanyun
Pan, Zhengbo
Cheng, Weisong
Xu, Linfei
Lin, Xingzhang
Lin, Yongfeng
Zhang, Liming
Ji, Guanghua
Lv, Xin
Wang, Dongguo
author_sort Liu, Sheng
collection PubMed
description PURPOSE: The overall survival of clear cell renal cell carcinoma (ccRCC) is poor. Markers for early detection and progression could improve disease outcomes. This study aims to reveal the potential pathogenesis of ccRCC by integrative bioinformatics analysis and to further develop new therapeutic strategies. PATIENTS AND METHODS: RNA-seq data of 530 ccRCC cases in TCGA were downloaded, and a comprehensive analysis was carried out using bioinformatics tools. Another 14 tissue samples were included to verify the expression of selected lncRNAs by qRT-PCR. DGIdb database was used to screen out potential drugs, and molecular docking was used to explore the interaction and mechanism between candidate drugs and targets. RESULTS: A total of 58 differentially expressed lncRNAs (DElncRNAs) and 660 differentially expressed mRNAs (DEmRNAs) were identified in ccRCC. LINC02038, FAM242C, LINC01762, and PVT1 were identified as the optimal diagnostic lncRNAs, of which PVT1 was significantly correlated with the survival rate of ccRCC. GO analysis of cell components showed that DEmRNAs co-expressed with 4 DElncRNAs were mainly distributed in the extracellular area and the plasma membrane, involved in the transport of metal ions, the transport of proteins across membranes, and the binding of immunoglobulins. Immune infiltration analysis showed that MDSC was the most correlated immune cells with PVT1 and key mRNA SIGLEC8. Validation analysis showed that GABRD, SIGLEC8 and CDKN2A were significantly overexpressed, while ESRRB, ELF5 and UMOD were significantly down-regulated, which was consistent with the expression in our analysis. Furthermore, 84 potential drugs were screened by 6 key mRNAs, of which ABEMACICLIB and RIBOCICLIB were selected for molecular docking with CDKN2A, with stable binding affinity. CONCLUSION: In summary, 4 key lncRNAs and key mRNAs of ccRCC were identified by integrative bioinformatics analysis. Potential drugs were screened for the treatment of ccRCC, providing a new perspective for disease diagnosis and treatment.
format Online
Article
Text
id pubmed-10238222
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-102382222023-06-04 Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas Liu, Sheng Shi, Guanyun Pan, Zhengbo Cheng, Weisong Xu, Linfei Lin, Xingzhang Lin, Yongfeng Zhang, Liming Ji, Guanghua Lv, Xin Wang, Dongguo Int J Gen Med Original Research PURPOSE: The overall survival of clear cell renal cell carcinoma (ccRCC) is poor. Markers for early detection and progression could improve disease outcomes. This study aims to reveal the potential pathogenesis of ccRCC by integrative bioinformatics analysis and to further develop new therapeutic strategies. PATIENTS AND METHODS: RNA-seq data of 530 ccRCC cases in TCGA were downloaded, and a comprehensive analysis was carried out using bioinformatics tools. Another 14 tissue samples were included to verify the expression of selected lncRNAs by qRT-PCR. DGIdb database was used to screen out potential drugs, and molecular docking was used to explore the interaction and mechanism between candidate drugs and targets. RESULTS: A total of 58 differentially expressed lncRNAs (DElncRNAs) and 660 differentially expressed mRNAs (DEmRNAs) were identified in ccRCC. LINC02038, FAM242C, LINC01762, and PVT1 were identified as the optimal diagnostic lncRNAs, of which PVT1 was significantly correlated with the survival rate of ccRCC. GO analysis of cell components showed that DEmRNAs co-expressed with 4 DElncRNAs were mainly distributed in the extracellular area and the plasma membrane, involved in the transport of metal ions, the transport of proteins across membranes, and the binding of immunoglobulins. Immune infiltration analysis showed that MDSC was the most correlated immune cells with PVT1 and key mRNA SIGLEC8. Validation analysis showed that GABRD, SIGLEC8 and CDKN2A were significantly overexpressed, while ESRRB, ELF5 and UMOD were significantly down-regulated, which was consistent with the expression in our analysis. Furthermore, 84 potential drugs were screened by 6 key mRNAs, of which ABEMACICLIB and RIBOCICLIB were selected for molecular docking with CDKN2A, with stable binding affinity. CONCLUSION: In summary, 4 key lncRNAs and key mRNAs of ccRCC were identified by integrative bioinformatics analysis. Potential drugs were screened for the treatment of ccRCC, providing a new perspective for disease diagnosis and treatment. Dove 2023-05-29 /pmc/articles/PMC10238222/ /pubmed/37275334 http://dx.doi.org/10.2147/IJGM.S409711 Text en © 2023 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Sheng
Shi, Guanyun
Pan, Zhengbo
Cheng, Weisong
Xu, Linfei
Lin, Xingzhang
Lin, Yongfeng
Zhang, Liming
Ji, Guanghua
Lv, Xin
Wang, Dongguo
Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title_full Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title_fullStr Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title_full_unstemmed Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title_short Integrated Bioinformatics Analysis for the Identification of Key lncRNAs, mRNAs, and Potential Drugs in Clear Cell Renal Cell Carcinomas
title_sort integrated bioinformatics analysis for the identification of key lncrnas, mrnas, and potential drugs in clear cell renal cell carcinomas
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10238222/
https://www.ncbi.nlm.nih.gov/pubmed/37275334
http://dx.doi.org/10.2147/IJGM.S409711
work_keys_str_mv AT liusheng integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT shiguanyun integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT panzhengbo integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT chengweisong integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT xulinfei integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT linxingzhang integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT linyongfeng integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT zhangliming integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT jiguanghua integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT lvxin integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas
AT wangdongguo integratedbioinformaticsanalysisfortheidentificationofkeylncrnasmrnasandpotentialdrugsinclearcellrenalcellcarcinomas